Significant increase in systemic exposure of atorvastatin after biliopancreatic diversion with duodenal switch

Clinical Pharmacology and Therapeutics

Volumn 87, Issue 6, 2010, Pages 699-705

  Skottheim, I B ^a   Jakobsen, G S ^b   Stormark, K ^b   Christensen, H ^a   Hjelmesaeth J ^b   Jenssen, T ^a,c   Asberg A ^a   Sandbu, R ^b  

^a UNIVERSITY OF OSLO   (Norway)

^b VESTFOLD HOSPITAL TRUST   (Norway)

^c UNIVERSITY OF TROMSØ   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN;

AREA UNDER THE CURVE; ARTICLE; BARIATRIC SURGERY; BILIOPANCREATIC BYPASS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EXPOSURE; MALABSORPTION; MORBID OBESITY; PRIORITY JOURNAL; SMALL INTESTINE; TITRIMETRY; WEIGHT REDUCTION;

ADULT; AGED; AREA UNDER CURVE; BILIOPANCREATIC DIVERSION; BIOLOGICAL AVAILABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DUODENUM; FEMALE; FOLLOW-UP STUDIES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTESTINE, SMALL; MALE; MIDDLE AGED; OBESITY, MORBID; PROSPECTIVE STUDIES; PYRROLES;

EID: 77952583699     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.32     Document Type: Article

References (50)

1. Santry, H.P., Gillen, D.L. & Lauderdale, D.S. Trends in bariatric surgical procedures. JAMA 294, 1909-1917 (2005).
2. Sjöström, L. et al.; Swedish Obese Subjects Study Scientifc Group. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N. Engl. J. Med. 351, 2683-2693 (2004)
3. Gastrointestinal surgery for severe obesity: National Institutes of Health Consensus Development Conference Statement. Am. J. Clin. Nutr. 55, 615-619 (1992).
4. WHO. Obesity: Preventing and Managing the Global Epidemic (Geneva, Switzerland, 1997).
5. Farrell, T.M., Haggerty, S.P., Overby, D.W., Kohn, G.P., Richardson, W.S. & Fanelli, R.D. Clinical application of laparoscopic bariatric surgery: an evidence-based review. Surg. Endosc. 23, 930-949 (2009).
6. 2) compared with gastric bypass. Ann. Surg. 244, 611-619 (2006).
7. Skottheim, I.B. et al. Signifcantly altered systemic exposure to atorvastatin acid following gastric bypass surgery in morbidly obese patients. Clin. Pharmacol. Ther. 86, 311-318 (2009).
8. Shimada, T., Yamazaki, H., Mimura, M., Inui, Y. & Guengerich, F.P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270, 414-423 (1994).
9. Paine, M.F. et al. First-pass metabolism of midazolam by the human intestine. Clin. Pharmacol. Ther. 60, 14-24 (1996).
10. de Wildt, S.N., Kearns, G.L., Leeder, j.S. & van den Anker, j.N. Cytochrome P450 3A: ontogeny and drug disposition. Clin. Pharmacokinet. 37, 485-505 (1999).
11. Beringer, P.M. & Slaughter, R.L. Transporters and their impact on drug disposition. Ann. Pharmacother. 39, 1097-1108 (2005).
12. Mealey, K.L. Therapeutic implications of the MDR-1 gene. J. Vet. Pharmacol. Ther. 27, 257-264 (2004).
13. Paine, M.F. et al. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J. Pharmacol. Exp. Ther. 283, 1552-1562 (1997).
14. McKinnon, R.A. & McManus, M.E. Localization of cytochromes P450 in human tissues: implications for chemical toxicity. Pathology 28, 148-155 (1996).
15. Nakamura, T. et al. Real-time quantitative polymerase chain reaction for MDR1, MRP1, MRP2, and CYP3A-mRNA levels in Caco-2 cell lines, human duodenal enterocytes, normal colorectal tissues, and colorectal adenocarcinomas. Drug Metab. Dispos. 30, 4-6 (2002).
16. Canaparo, R. et al. Expression of CYP3A isoforms and P-glycoprotein in human stomach, jejunum and ileum. Clin. Exp. Pharmacol. Physiol. 34, 1138-1144 (2007).
17. Thörn, M., Finnström, N., Lundgren, S., Rane, A. & Lööf, L. Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract. Br. J. Clin. Pharmacol. 60, 54-60 (2005).
18. Berggren, S. et al. Gene and protein expression of P-glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestine. Mol. Pharm. 4, 252-257 (2007).
19. Zhang, Q.Y., Dunbar, D., Ostrowska, A., Zeisloft, S., Yang, j. & Kaminsky, L.S. Characterization of human small intestinal cytochromes P-450. Drug Metab. Dispos. 27, 804-809 (1999). (Pubitemid 29297778)
20. Mouly, S. & Paine, M.F. P-glycoprotein increases from proximal to distal regions of human small intestine. Pharm. Res. 20, 1595-1599 (2003).
21. Fojo, A.T., Ueda, K., Slamon, D.j., Poplack, D.G., Gottesman, M.M. & Pastan, I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc. Natl. Acad. Sci. U.S.A. 84, 265-269 (1987).
22. Fricker, G., Drewe, J., Huwyler, J., Gutmann, H. & Beglinger, C. Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation. Br. J. Pharmacol. 118, 1841-1847 (1996).
23. Zimmermann, C., Gutmann, H., Hruz, P., Gutzwiller, j.P., Beglinger, C. & Drewe, j. Mapping of multidrug resistance gene 1 and multidrug resistance-associated protein isoform 1 to 5 mRNA expression along the human intestinal tract. Drug Metab. Dispos. 33, 219-224 (2005).
24. Englund, G. et al. Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells. Eur. J. Pharm. Sci. 29, 269-277 (2006).
25. Schachter, M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam. Clin. Pharmacol. 19, 117-125 (2005).
26. Williams, D. & Feely, J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin. Pharmacokinet. 41, 343-370 (2002).
27. Lilja, J.J., Kivistö, K.T. & Neuvonen, P.j. Grapefruit juice-simvastatin interaction: efect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin. Pharmacol. Ther. 64, 477-483 (1998).
28. Ando, H. et al. Efects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin. Br. J. Clin. Pharmacol. 60, 494-497 (2005).
29. Lilja, J.J., Kivistö, K.T. & Neuvonen, P.J. Grapefruit juice increases serum concentrations of atorvastatin and has no efect on pravastatin. Clin. Pharmacol. Ther. 66, 118-127 (1999).
30. Tubic-Grozdanis, M. et al. Pharmacokinetics of the CYP 3A substrate simvastatin following administration of delayed versus immediate release oral dosage forms. Pharm. Res. 25, 1591-1600 (2008).
31. Tannergren, C., Bergendal, A., Lennernäs, H. & Abrahamsson, B. Toward an increased understanding of the barriers to colonic drug absorption in humans: implications for early controlled release candidate assessment. Mol. Pharm. 6, 60-73 (2009).
32. Seidegård, J., Nyberg, L. & Borgå, O. Presystemic elimination of budesonide in man when administered locally at diferent levels in the gut, with and without local inhibition by ketoconazole. Eur. J. Pharm. Sci. 35, 264-270 (2008).
33. Hermann, M. et al. Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy. Clin. Pharmacol. Ther. 79, 532-539 (2006).
34. Wrighton, S.A. et al. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol. Pharmacol. 38, 207-213 (1990).
35. Kuehl, P. et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27, 383-391 (2001).
36. Hofmeyer, S. et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA 97, 3473-3478 (2000).
37. Bernstine, H. et al. Gastric emptying is not afected by sleeve gastrectomy-scintigraphic evaluation of gastric emptying after sleeve gastrectomy without removal of the gastric antrum. Obes. Surg. 19, 293-298 (2009).
38. Melissas, J. et al. Sleeve gastrectomy-a "food limiting" operation. Obes. Surg. 18, 1251-1256 (2008).
39. Radulovic, L.L., Cilla, D.D., Posvar, E.L., Sedman, A.j. & Whitfeld, L.R. Efect of food on the bioavailability of atorvastatin, an HMG-CoA reductase inhibitor. J. Clin. Pharmacol. 35, 990-994 (1995).
40. Whitfeld, L.R., Stern, R.H., Sedman, A.j., Abel, R. & Gibson, D.M. Efect of food on the pharmacodynamics and pharmacokinetics of atorvastatin, an inhibitor of HMG-CoA reductase. Eur. J. Drug Metab. Pharmacokinet. 25, 97-101 (2000).
41. Marterre, W.F., Hariharan, S., First, M.R. & Alexander, j.W. Gastric bypass in morbidly obese kidney transplant recipients. Clin. Transplant. 10, 414-419 (1996).
42. Thielke, J., Martin, J., Weber, F.L., Schroeder, T.J., Goretsky, S. & Hanto, D.W. Pharmacokinetics of tacrolimus and cyclosporine in short-bowel syndrome. Liver Transpl. Surg. 4, 432-434 (1998).
43. Dudrick, S.J., Daly, J.M., Castro, G. & Akhtar, M. Gastrointestinal adaptation following small bowel bypass for obesity. Ann. Surg. 185, 642-648 (1977).
44. Stock-Damgé, C., Aprahamian, M., Raul, F., Marescaux, j. & Scopinaro, N. Small-intestinal and colonic changes after biliopancreatic bypass for morbid obesity. Scand. J. Gastroenterol. 21, 1115-1123 (1986).
45. Stein, T.A. & Wise, L. Functional adaptation of the intestinal mucosal enzymes after jejunoileal bypass for morbid obesity. Am. J. Clin. Nutr. 31, 1143-1148 (1978).
46. Hermann, M., Christensen, H. & Reubsaet, j.L. Determination of atorvastatin and metabolites in human plasma with solid-phase extraction followed by LC-tandem MS. Anal. Bioanal. Chem. 382, 1242-1249 (2005).
47. Siegmund, W. et al. The efects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin. Pharmacol. Ther. 72, 572-583 (2002).
48. Katz, D.A. et al. CYP3A5 genotype has a dose-dependent efect on ABT-773 plasma levels. Clin. Pharmacol. Ther. 75, 516-528 (2004).
49. Lemahieu, W.P. et al. Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus. Am. J. Transplant. 5, 2236-2243 (2005).
50. European Medicines Agency Committee for Medicinal Products for Human Use. Note for Guidance on the Investigation of Bioavailability and Bioequivalence, CHMP/EWP/QWP/1401/98 (London 2001).